Enliven Therapeutics Files 8-K/A Amendment
Ticker: ELVN · Form: 8-K/A · Filed: May 29, 2024 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K/A |
| Filed Date | May 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, management-change, corporate-governance
TL;DR
Enliven Therapeutics filed an amendment to an 8-K regarding officer/director changes. Keep an eye on leadership shifts.
AI Summary
Enliven Therapeutics, Inc. filed an amendment (8-K/A) on May 29, 2024, to a previous report concerning events that occurred on April 8, 2024. The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The company, formerly known as IMARA Inc., is incorporated in Delaware and headquartered in Boulder, Colorado.
Why It Matters
This filing provides updated information regarding changes in Enliven Therapeutics' board and executive team, which can signal shifts in company strategy or governance.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially those concerning director and officer changes, can indicate internal shifts that may impact the company's direction.
Key Numbers
- 001-39247 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1523849 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- IMARA Inc. (company) — Former company name
- April 8, 2024 (date) — Earliest event date
- May 29, 2024 (date) — Filing date
- Boulder, Colorado (location) — Principal executive offices
FAQ
What specific events are being amended in this 8-K/A filing?
This 8-K/A amends information related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was Enliven Therapeutics' former name?
Enliven Therapeutics, Inc. was formerly known as IMARA Inc.
On what date were the earliest events reported in this filing?
The earliest event reported was on April 8, 2024.
When was this amendment filed with the SEC?
This amendment (8-K/A) was filed on May 29, 2024.
Where are Enliven Therapeutics' principal executive offices located?
Enliven Therapeutics' principal executive offices are located at 6200 Lookout Road, Boulder, Colorado, 80301.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-29 16:06:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ELVN The Nasdaq Global Se
Filing Documents
- d816859d8ka.htm (8-K/A) — 22KB
- 0001193125-24-149141.txt ( ) — 146KB
- elvn-20240408.xsd (EX-101.SCH) — 3KB
- elvn-20240408_lab.xml (EX-101.LAB) — 18KB
- elvn-20240408_pre.xml (EX-101.PRE) — 11KB
- d816859d8ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Enliven Therapeutics, Inc. Date: May 29, 2024 By: /s/ Samuel Kintz Name: Samuel Kintz Title: President and Chief Executive Officer